Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tamsulosin in Children with Voiding Disorders
NCT02266524Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2005
- Primary completion
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in Voiding dysfunction (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of the analyte in plasma up to 26 hours, Time from dosing to maximum concentration up to 26 hours and 2 more. Started Jan 2005; status: completed.
02
Drugs
tamsulosin
03
Conditions
Voiding dysfunction
Beyond the preview
Go deeper on NCT02266524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266524.